Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

Marie Skłodowska-Curie Action · Running

INTRABRAIN Nanoplatforms and Oncolytic viruses for novel cancer immunotherapy strategies

Coordinator
Helsingin Yliopisto, Finland
Runs
1 March 2026 to 28 February 2030
Status
Running
EU funding
€4.3m
Total cost
—
Partners
13 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101227308

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunotherapy is a potential key weapon in the fight against cancer, in general, and Glioblastoma Multiforme (GBM), in particular. Still, a better understanding of how immunotherapy can be leveraged in GBM patients is direly needed. Disease complexity and blood-brain barrier impermeability mean that a standard vaccinology approach will not work. As part of a novel cancer management strategy, this project aims to create more efficacious vaccines using polymeric nanoparticles and self-assembled nanoplatforms in combination with modified oncolytic viruses.

We will use biodegradable nanomaterials to protect the OV from body clearance and exploit the intranasal route for efficient delivery to the brain. We will incorporate the IL12 gene into a recombinant adenovirus vector backbone, which will stay under the nanoparticle protection until the drug reaches the tumour microenvironment and is released to reverse tumour-induced immunosuppression. This new strategy offers an efficient alternative to the current standard-of care - i.e. labour-intensive immunotherapy and possibly chemoradiation.

The development of an off-the-shelf product, which provides additional anti-tumoral effects at different levels, would significantly prolong the life expectancy of GBM patients. This bioprocess would be scalable for production and compatible with Good Manufacturing Practices. The administration strategies, safety and efficacy of the anti-cancer agent will be validated in animal GBM models. The main training objective is to educate a strongly needed generation of interdisciplinary specialists in tight collaboration with large pharmacological industries, academia, and clinical centres.

This will not only educate 14 outstanding early-stage researchers, but also greatly enhance their career perspectives through the unique opportunity to conduct transdisciplinary research and embark on a high-quality training in both academic and entrepreneurial industrial environments.

Who is involved

OrganisationCityCountryRole
Helsingin YliopistoHelsinkiFinlandCoordinator
Friedrich-Alexander-Universitaet Erlangen-NuernbergErlangenGermanyParticipant
Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic BiomaguneSan SebastianSpainParticipant
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainAssociatedpartner
Image Guided Therapy SAPessacFranceAssociatedpartner
Technion - Israel Institute of TechnologyHaifaIsraelAssociatedpartner
Technion Research and Development Foundation LtdHaifaIsraelParticipant
Universita Degli Studi Di Napoli Federico IiNapoliItalyParticipant
Universita Degli Studi Di Roma Tor VergataRomaItalyParticipant
Universita Degli Studi Gabriele D'annunzio Di Chieti-PescaraChietiItalyParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
The University of ExeterExeterUnited KingdomParticipant
University of GlasgowGlasgowUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI